Narayanapillai et al. showed that chronic inflammation that is characteristic for smokers diagnosed with COPD creates favourable conditions for immunosuppressive microenvironment with higher PD-L1 expression in tumour tissue, and precisely this type of tumours might have a greater benefit from immune checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.